Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Marie Skłodowska-Curie Action · Running

ANA-KIN Advancing Novel Approaches in Kinase Interface Networks

Coordinator
Aristotelio Panepistimio Thessalonikis, Greece
Runs
1 September 2026 to 31 August 2030
Status
Running
EU funding
€3.6m
Total cost
—
Partners
20 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101312304

What the project is doing

In the project's own words, from its summary on CORDIS.

ANA-KIN will train 12 doctoral researchers to redefine kinase drug discovery by pioneering strategies that move beyond the ATP site. Protein kinases are among the most validated drug targets, yet nearly all approved inhibitors still target the highly conserved ATP cleft, a 20-year-old paradigm that has seen remarkably little conceptual renewal. Dimerization and substrate interfaces, by contrast, are far less conserved and represent fundamentally different regulatory entry points.

However, the field currently lacks the generalisable assays and cross-disciplinary integration needed to systematically exploit them. To address this, ANA-KIN establishes the first coordinated European framework dedicated to mapping and modulating kinase interfaces. It brings together leading expertise in chemical biology, structural biophysics, AI-guided design, PPI-focused discovery technologies and cellular mechanism across 12 academic laboratories and 10 academic and industrial partners.

This integrated effort will produce ATP-locking chemical tools, modular interface-focused assays, high-resolution conformational maps and complementary bicyclic peptide/small-molecule discovery engines that collectively enable the systematic identification of interface-selective modulators. The training programme couples interdisciplinary co-supervision, intersectoral secondments and network-wide scientific schools with structured development in scientific, transferable, open-science and entrepreneurial skills.

Robust governance (Supervision Oversight Board and Ombudsperson) ensures transparent supervision, while diversity and culture-of-care measures foster an inclusive and supportive environment. Through this coordinated research and training ecosystem, ANA-KIN will generate the tools, mechanistic foundations and interdisciplinary expertise required to unlock kinase interfaces as a new therapeutic frontier, while preparing a cohort capable of driving next-generation kinase drug discovery in Europe

Topics

Who is involved

OrganisationCityCountryRole
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Skylight Therapeutics BVLeuvenBelgiumAssociatedpartner
Vib VzwZwijnaarde - GentBelgiumParticipant
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandAssociatedpartner
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Universitat Des SaarlandesSaarbruckenGermanyParticipant
Enzyquest Private CompanyHeraklionGreeceAssociatedpartner
Panepistimio KritisRethimnoGreeceParticipant
Universidad Pompeu FabraBarcelonaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite D'aix MarseilleMarseilleFranceAssociatedpartner
Servier Gyogyaszati Vegytani Kutatointezet Zartkoruen Mukodo ReszvenytarsasagBudapestHungaryAssociatedpartner
Universiteit LeidenLeidenNetherlandsParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
Northeastern UniversityBoston MaUnited StatesAssociatedpartner
The Scripps Research Institute CorporationLa JollaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI